Fibrinogen and factor XIII were measured in sixty-four women with recently detected gynaecological tumours. Twenty-six of these tumours were benign and 32 were malignant: of the last group, nine patients had metastases. No patient showed clinical signs of bleeding or thrombosis. A reference group consisted of 31 agematched healthy women. For fibrinogen, no significant deviation between the patient groups and the control group was found. The median values of factor XIII were higher in the benign tumour group than in the control group. In patients with a gynaecological tumour and metastases, factor XIII was significantly lower than in the non-metastasized malignancy group or in the benign tumour group.
Introduction
Since an enzymatic assay for pläsma factor XIII activity became available, pläsma factor concentrations have been measured in various clinical conditions: Crohn's disease (1), colitis ulcerösa (2), systemic haematological disorders (7), morbus HennochSchönlein (3), bacterial infections (3) and several types of neoplastic malignancies (4, 5, 6) . Little is known about the role of factor XIII in cancer (3) . Factor XIII has been found in connective tissue stroma (7) , where it may cross-link fibrin to the surface of neoplastic cells without decreasing their viability (8) , and provide striu> türal integrity and vascularization support to the tumour mass (9) . It has been reported that thrombin and factor XIII show mitogenic activity towards some malignant cell types in vitro (10) , There are, to our knowledge, no reports on the behaviour of plasmatic factor XIII in gynaecological oiieology. Therefore, it was the aim of this study to investigate factor XIII in pläsma of patients with benign and malignant gynaecological tumours. Simultaneously the acute phase reactant fibrinogeni was determined to assess whether plasmatic factor XIII may also behave like an acute phase protein.
Materials and Methods

Patients
Plasma samples were collected from 58 patients with a benign or malignant gynaecologicial tumour. The diagnosis was later confirmed by histology. On admission to the hospital no patient showed clinical signs of bleeding or thrombosis. Twenty-six patients had a benign disease (tab. 1) and 32 patients a malignancy (tab. 2). In the latter group nine patients had histologically proven metastases, mostly in lymph nodes or peritoneal tissue. The use of medication was excluded. A reference group consisted of 31 agematehed subjectively healthy women.
Samples
The Coagulation constituents were determined in citrated pläsma prepared by centrifugation of nine volumes of freshly drawn blood with one volume trisodium citräte (0. i l mol/1) for 10 min (1600 g) at 25 °C. The pläsma was stored at -70 °C in plastic tubes and thawed with tap water at 37 °C for 5 min before serial analysis. 
Results
In table l the basic characteristics of the patients with a benign disease are given. Ovarian cysts occur mostly in this group. Table 2 shows the various tumour types in the patients with a malignancy. Most of the patients appeared to have a cervix or an ovarian carcinoma. Metastases were especially present in the ovarian carcinoma group.
In table 3 a comparison of the benign tumour group, the total malignant tumour group and an age-matched control group is given. Except for age, the quantities showed a non-Gaussian distribution, and the results are presented äs median values and interquartile ranges. Tlie group with a benign gynaecological tumour showed statistically significant, higher median values for factor XIII, compared with the age-matched control group. The median value for factor XIII in the malignant tumour group was not significantly different from that in the age-matched control group.
In A significant proportion of the factor XIII values were decreased in the metastasis group, compared with the other two patient groups.
Discussion
No significant differences were found in the fibrinogen levels of patients with a benign or malignant gynaecological tumour, nor in any of these groups compared with the control group.
Factor XIII values in patients with a benign gynaecological tumour and in patients with a non-metastasized malignant tumour, however, were significantly enhanced in comparison with the control group. An explanation for this phenomenon might be that additional tissue factor XIII is released from these tumours. This possibility is strengthened by a recent review by Aeschliman F & Paulsson (11), on the localization and function of i factor XIII, in which it is shown that tissue factor XIII is nearly ubiquitous. Factor XIII values were significantly decreased in patients with metastases compared with the patients without metastases and the patients with benign tumours. This finding might be relevant, since factor XIII is important for the cross-linking of proteins other than fibrin. Lowered factor XIII concentrations have been reported in malignant melanoma,. breast cancer and gastric cancer (4, 5, 12) , but decreased factor XIII has not been found in patients with hing cancer or colonic cancer (13, 14) .
An explanation for the decrease might be the consuriiption of factor XIII during the cross-linking of proteins in and around the tumour. Consumption during locäl activation of the clotting system promotes tumour mainte·-nance and perpetuation by conversion of fibrinogen to fibrin (9) . Moreover, factor XIII is used for the crosslinking oif fibrin and a 2 -antiplasmin to the surface of neoplastic cells (7, 8) , which promotes tumour growth and prevents fibrinolytic degradation. The presenee of thrombin and factor XIII on the tumour site may therefore contribute to tumour progression (10) . In an earlier study it was established that patients with a metastasizedgynaecological tumour displäyed high levels of coagulation activation and reactive fibrinolysis. Therefore, redueed plasma factor XIII concentrations may at least pärtly be due to enhanced consumption for cröss^linking purposes. In addition, the factor XIII reduction may be the result of enhanced unspecific proteolysis by e. g. neutrophil elastase. Low activities of factor XIII have been reported in other diseases with increased elastasetti-antitrypsin complexes (15, 16, 17 ). An enhanced proteolyis of factor XIII in patients with metastases is possible, since an elevation of the proteolytic activity has also been reported in tumour patients.
In conclusion, factor XIII and fibrinogen did not behave synchronously in the different gynaecological tumour groups. This finding does not support the idea that factor XIII might possess acute phase charactertistics. For the clinician, however, the determination of factor XIII may provide an aid to the diagnosis of inetastasis in pätients with gynaecological tumours.
